The drug-pricing problem no one wants to talk about

The drug-pricing problem no one wants to talk about

Tackling the misuse of patents by some big pharma companies could go a long way to bringing down drug prices.

The Unit Problem Nobody Wants to Fix

A twenty-eight-fold error is not a rounding discrepancy. It is not a minor data-entry artifact or an acceptable margin of analytical noise. Yet that is precisely the magnitude of pricing distortion that the National Council for Prescription Drug Programs has documented when billing units and CMS unit types fall out of alignment — a scenario that occurs more often than anyone in the pharmaceutical data business cares to admit. The problem is stru…